King Luther Capital Management Corp Invests $2.27 Million in Prestige Consumer Healthcare Inc. $PBH

King Luther Capital Management Corp bought a new position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) in the 3rd quarter, HoldingsChannel reports. The institutional investor bought 36,347 shares of the company’s stock, valued at approximately $2,268,000.

Several other hedge funds also recently added to or reduced their stakes in PBH. Allspring Global Investments Holdings LLC grew its position in Prestige Consumer Healthcare by 4.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,592,375 shares of the company’s stock worth $100,893,000 after purchasing an additional 70,376 shares during the period. Geode Capital Management LLC grew its holdings in Prestige Consumer Healthcare by 0.7% during the second quarter. Geode Capital Management LLC now owns 1,413,041 shares of the company’s stock worth $112,843,000 after acquiring an additional 9,455 shares during the period. Westwood Holdings Group Inc. grew its holdings in Prestige Consumer Healthcare by 2.4% during the second quarter. Westwood Holdings Group Inc. now owns 881,908 shares of the company’s stock worth $70,420,000 after acquiring an additional 20,626 shares during the period. Bank of America Corp DE raised its position in Prestige Consumer Healthcare by 19.1% during the second quarter. Bank of America Corp DE now owns 721,371 shares of the company’s stock valued at $57,601,000 after acquiring an additional 115,459 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in Prestige Consumer Healthcare by 12.9% in the second quarter. The Manufacturers Life Insurance Company now owns 553,407 shares of the company’s stock valued at $44,190,000 after acquiring an additional 63,168 shares during the period. 99.95% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on PBH. Zacks Research raised shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research note on Monday, November 10th. Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Thursday, January 22nd. Canaccord Genuity Group dropped their price target on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Finally, Jefferies Financial Group decreased their price objective on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research report on Friday, January 30th. Three research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, Prestige Consumer Healthcare has an average rating of “Hold” and an average price target of $80.60.

Insiders Place Their Bets

In related news, VP Jeffrey Zerillo sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $65.93, for a total value of $65,930.00. Following the transaction, the vice president directly owned 41,048 shares of the company’s stock, valued at approximately $2,706,294.64. This trade represents a 2.38% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders have sold 2,000 shares of company stock valued at $125,930. Company insiders own 1.40% of the company’s stock.

Prestige Consumer Healthcare Price Performance

Prestige Consumer Healthcare stock opened at $69.59 on Friday. The stock has a market capitalization of $3.29 billion, a P/E ratio of 18.41, a P/E/G ratio of 2.17 and a beta of 0.43. The company’s fifty day moving average price is $64.50 and its 200 day moving average price is $63.48. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.93 and a current ratio of 3.11. Prestige Consumer Healthcare Inc. has a 1 year low of $57.25 and a 1 year high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, February 5th. The company reported $1.14 earnings per share for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The company had revenue of $283.44 million for the quarter, compared to analyst estimates of $286.93 million. During the same quarter in the prior year, the company posted $1.22 earnings per share. The business’s revenue was down 2.4% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. As a group, equities research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).